semaglutide alzheimer trial Novo Nordisk says semaglutide, the drug used in Wegovy and Ozempic, does not slow Alzheimer's progression, despite early real-world signals that prompted two major Evoke trials involving more than 3,800 participants aged Two of the most anticipated
Description
Apart from the gall bladder issues for which Ozempic is facing a lot of lawsuits now, its maker Novo Nordisk is destined to deal with stomach paralysis lawsuits
The Look AHEAD trial: bone loss at 4-year follow-up in type 2 diabetes
Restarting at your regular maintenance dose carries no increased risk and requires no dose adjustment
99 Until more robust trials confirm their safety specifically in patients with reduced LVEF, GLP-1 RAs should be used cautiously in this population
A high dose can cause seizures, respiratory problems, and overdose
